CHICAGO: Acumen Pharmaceuticals (ABOS.O) announced on Sunday that an experimental treatment for Alzheimer’s disease that targets a novel version of the harmful protein beta amyloid in the brain has passed an initial safety test and will move on to a larger trial.
According to the manufacturer, the medication, ACI193, was well tolerated throughout its initial human testing. At the Alzheimer’s Association’s International Conference in Amsterdam, the findings of a randomised, placebo-controlled research including 62 patients with early Alzheimer’s disease were presented.